Blood vessels made through tissue engineering are being trialled in humans and may provide a future source of grafts from coronary applications. That is the latest from a California-based company, Cytograft, who presented details of their methods and current human trial at the AHA meeting. Todd McAllister told Audio Medica how it all works.
[audio:https://www.audiomedica.com/podcasting/aha2005/Todd_McAllister.mp3]
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
